Your SlideShare is downloading. ×
0
Neurofibromatoses – pipeline review, h2 2012
Neurofibromatoses – pipeline review, h2 2012
Neurofibromatoses – pipeline review, h2 2012
Neurofibromatoses – pipeline review, h2 2012
Neurofibromatoses – pipeline review, h2 2012
Neurofibromatoses – pipeline review, h2 2012
Neurofibromatoses – pipeline review, h2 2012
Neurofibromatoses – pipeline review, h2 2012
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Neurofibromatoses – pipeline review, h2 2012

98

Published on

H2 2012 | Aarkstore.com || Neurofibromatoses – pipeline review, h2 2012

H2 2012 | Aarkstore.com || Neurofibromatoses – pipeline review, h2 2012

Published in: News & Politics
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
98
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • www.aarkstore.in
  • Transcript

    • 1. You can also request for sample page of abovemention reports on sample@aarkstore.com
    • 2. Pages : 79PDF - $ 2000 | Site Licence - $ 4000 $ | Enterprise License - $6000 |
    • 3. Summary Global Markets Direct’s, Neurofibromatoses - Pipeline Review, H2 2012,provides an overview of the indication’s therapeutic pipeline. This reportprovides information on the therapeutic development forNeurofibromatoses, complete with latest updates, and special features onlate-stage and discontinued projects. It also reviews key players involved inthe therapeutic development for Neurofibromatoses. Neurofibromatoses -Pipeline Review, Half Year is built using data and information sourced fromGlobal Markets Direct’s proprietary databases, Company/Universitywebsites, SEC filings, investor presentations and featured press releasesfrom company/university sites and industry-specific third party sources,put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based onthe availability and relevance of data for the indicated disease.
    • 4. Scope - A snapshot of the global therapeutic scenario for Neurofibromatoses.- A review of the Neurofibromatoses products under development by companiesand universities/research institutes based on information derived fromcompany and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Neurofibromatoses.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the mostpromising pipeline.- Devise corrective measures for pipeline projects by understandingNeurofibromatoses pipeline depth and focus of Indication therapeutics.
    • 5. Table of Contents : List of Tables 6List of Figures 6Introduction 7Global Markets Direct Report Coverage 7Neurofibromatoses Overview 8Therapeutics Development 9An Overview of Pipeline Products for Neurofibromatoses 9Neurofibromatoses Therapeutics under Development by Companies 11Neurofibromatoses Therapeutics under Investigation byUniversities/Institutes 12Mid Clinical Stage Products 14Comparative Analysis 14Early Clinical Stage Products 15Comparative Analysis 15Discovery and Pre-Clinical Stage Products 16Comparative Analysis 16Neurofibromatoses Therapeutics – Products under Development byCompanies 17Neurofibromatoses Therapeutics – Products under Investigation byUniversities/Institutes 18………………….
    • 6. Please follow link if you want More RelatedReports :Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=PipelineReview, H2 2012&PubId=&pagenum=1
    • 7. Related Reports:Hereditary Angioedema (HAE) – Pipeline Review, H2 2012Dermatomycoses – Pipeline Review, H2 2012Familial Adenomatous Polyposis Coli – Pipeline Review, H2 2012Tinnitus – Pipeline Review, H2 2012Premenstrual Syndrome – Pipeline Review, H2 2012Wrinkles – Pipeline Review, H2 2012Genital Warts (Condylomata Acuminata) – Pipeline Review, H22012Fabry Disease – Pipeline Review, H2 2012Thyroid Gland Disorders – Pipeline Review, H2 2012Proteinuria – Pipeline Review, H2 2012Viral Conjunctivitis – Pipeline Review, H2 2012Mixed Dyslipidemia – Pipeline Review, H2 2012Keratitis – Pipeline Review, H2 2012Generalized Seizures – Pipeline Review, H2 2012Cataract – Pipeline Review, H2 2012Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review,H2 2012Thrombocythaemia Myelofibrosis – Pipeline Review, H2 2012
    • 8. For More details about above & otherReports plz contact :LavanyaAarkstore.comContact: Marketing team Mob.No.918149852585Email: enquiry@aarkstore.com ,discount@aarkstore.comURL: http://www.aarkstore.comhttp://in.linkedin.com/in/aarkstorehttp://www.facebook.com/aarkstore

    ×